search
Back to results

OCT Guided vs COmplete Pci in patieNts With sT Segment Elevation myocArdial infarCtion and mulTivessel Disease (OCT-CONTACT)

Primary Purpose

Acute Coronary Syndrome

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
OCT - optical coherence tomography
Sponsored by
Azienda Ospedaliera Città della Salute e della Scienza di Torino
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Coronary Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Patients with STEMI and residual non culprit CAD
  2. Informed consent

Exclusion Criteria:

  1. Refusal or inability to provide informed consent.
  2. < 18 years of age
  3. Cardiogenic shock
  4. Previous Coronary Artery Bypass Grafting (CABG
  5. Indication for revascularization by CABG.
  6. eGFR < 30 ml/min/m2
  7. ULM stenosis
  8. Estimated life expectancy < 3 year
  9. Non culprit CTO lesion

Sites / Locations

  • Città della Salute e della Scienza di TorinoRecruiting
  • Ospedale San Luigi Gonzaga, OrbassanoRecruiting
  • Ospedale di RivoliRecruiting
  • AOU Città della Salute e della Scienza di TorinoRecruiting
  • Ospedale San Giovanni BoscoRecruiting
  • Citta della SaluteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Exsperimental Arm

Control Arm

Arm Description

Outcomes

Primary Outcome Measures

Major adverse cardiovascular events (MACE)
Composite endopoint of all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, unplanned revascularization.

Secondary Outcome Measures

Secondary efficacy end-points
Rate of all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, unplanned revascularization taking separately.

Full Information

First Posted
May 5, 2021
Last Updated
May 7, 2021
Sponsor
Azienda Ospedaliera Città della Salute e della Scienza di Torino
search

1. Study Identification

Unique Protocol Identification Number
NCT04878133
Brief Title
OCT Guided vs COmplete Pci in patieNts With sT Segment Elevation myocArdial infarCtion and mulTivessel Disease
Acronym
OCT-CONTACT
Official Title
OCT Guided vs COmplete Pci in patieNts With sT Segment Elevation myocArdial infarCtion and mulTivessel Disease
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2021 (Actual)
Primary Completion Date
January 31, 2023 (Anticipated)
Study Completion Date
January 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda Ospedaliera Città della Salute e della Scienza di Torino

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
STEMI patients with multivessel disease will be randomized to complete PCI versus PCI driven by high risk criteria of plaques evaluated with OCT
Detailed Description
In patients with ST segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significally reduces the risk of cardiovascular death. How to manage in this setting non-culprit lesion in patients with multivessel disease still remain a matter of debate. Recently, the COMPLETE trial showed that complete PCI of every coronary stenosis > 70% (or 50-69% lesions with FFR < 0.8) reduces risk of myocardial infarction (MI) and unstable angina (UA) at 3 years compared with culprit-lesion PCI [1]. Whether this findings are related to revascularization of every obstructive lesions rather than lesions with vulnerable-plaque characteristics, still remain unclear. In high risk patients such as STEMI patients, physiopathology of coronary plaque deeply differs from stable angina, mainly due to peculiar features of plaque. STEMI lesions, when evaluated at autopsy or at intracoronary imaging, showed a pro-thrombotic pattern, with high prevalence of thin cap fibro-atheroma, plaque rupture or thrombus, and a larger amount of lipids and macrophage [2-6]. In this setting, angiography, even when combined with fractional flow reserve evaluation (which can describe more accurately the functional impact of the plaque), has intrinsic limitations because of lack of information about plaque characteristics [7,8]. Optical coherence tomography (OCT) is the latest development in intravascular coronary imaging. Similarly to intravascular ultrasound (IVUS), OCT provides cross-sectional images of the vessel. However, instead of sound, OCT employs light for tissue analysis that enables visualization of the coronary lesions with almost microscopic precision [9,10]. This tool can find high risk vulnerable plaque without angiographic or functional signs of severity, helping from misdiagnosing and under-treating these lesions, that could benefit from PCI even more than obstructive lesions without vulnerable plaque characteristics. In an OCT substudy of the COMPLETE trial, researchers determined that half of patients had obstructive nonculprit lesions with vulnerable plaque, which could explain why complete revascularization conferred better outcomes than culprit lesion-only revascularization in the main trial. This substudy pointed out also a 20% of non-obstructive non-culprit lesions with vulnerable plaque caracteristics and up to 30% of obstructive non-culprit lesions without high risk morphology [11]. It suggest that a morphological approach to PCI in high risk patients can provide a more specific treatment compared with standard angiographic/functional approach. A correct identification of coronary plaque instability in a setting of STEMI patients could deeply impact in these patients risk of cardiovascular events, angina and re- hospitalization. Being coronary artery disease a pandemic disease with an important impact on nations health care, a reduction in events in these patients do not impact only on patients quality of life, but on health care system resources. Consequently, we propose a randomized controlled trial to evaluate the effective benefit of OCT guided vs complete PCI in STEMI patients with multivessels coronary artery disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Coronary Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients with STEMI who underwent successful culprit-lesion PCI will be enrolled after the index PCI. Eligible patients will be required to have residual multivessel disease, defined as at least one stenosis > 50 %. Patients will be randomized in a 1:1 fashion to OCT guided PCI of non-culprit lesions (Group A) vs complete PCI. (Group B)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
460 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Exsperimental Arm
Arm Type
Experimental
Arm Title
Control Arm
Arm Type
No Intervention
Intervention Type
Diagnostic Test
Intervention Name(s)
OCT - optical coherence tomography
Intervention Description
The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds. In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console.
Primary Outcome Measure Information:
Title
Major adverse cardiovascular events (MACE)
Description
Composite endopoint of all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, unplanned revascularization.
Time Frame
24 mounth after the recruitment in the study
Secondary Outcome Measure Information:
Title
Secondary efficacy end-points
Description
Rate of all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, unplanned revascularization taking separately.
Time Frame
24 mounth after the recruitment in the study
Other Pre-specified Outcome Measures:
Title
Safety end-points
Description
Rate of Acute kidney injury (AKI) following OCT vs complete guided PCI, defined according to the Acute Kidney Injury Network criteria
Time Frame
24 mounth after the recruitment in the study
Title
Safety end-points
Description
Rate of procedural complications following each PCI: periprocedural MI defined according to the Fourth Universal Definition of Myocardial Infarction [15], arterial access site complications, AKI
Time Frame
24 mounth after the recruitment in the study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with STEMI and residual non culprit CAD Informed consent Exclusion Criteria: Refusal or inability to provide informed consent. < 18 years of age Cardiogenic shock Previous Coronary Artery Bypass Grafting (CABG Indication for revascularization by CABG. eGFR < 30 ml/min/m2 ULM stenosis Estimated life expectancy < 3 year Non culprit CTO lesion
Facility Information:
Facility Name
Città della Salute e della Scienza di Torino
City
Torino
State/Province
Piemonte
ZIP/Postal Code
10100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabrizio D'Ascenzo, MD
Phone
+390116335570
Email
fabrizio.dascenzo@gmail.com
First Name & Middle Initial & Last Name & Degree
Fabrizio D'Ascenzo, MD
First Name & Middle Initial & Last Name & Degree
Mattia Peyracchia, MD
Facility Name
Ospedale San Luigi Gonzaga, Orbassano
City
Orbassano
ZIP/Postal Code
10043
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Enrico Cerrato
Phone
347 9317104
Email
enrico.cerrato@gmail.com
Facility Name
Ospedale di Rivoli
City
Rivoli
ZIP/Postal Code
10098
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giorgio Quadri
Phone
+ 393487936963
Email
lo.savio.luca88@gmail.com
Facility Name
AOU Città della Salute e della Scienza di Torino
City
Torino
ZIP/Postal Code
10126
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabrizio D'Ascenzo, MD
Phone
+390116336023
Email
fabrizio.dascenzo@gmail.com
Facility Name
Ospedale San Giovanni Bosco
City
Torino
ZIP/Postal Code
10144
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mario Iannacone
Phone
+393391812226
Email
mario.iannaccone@hotmail.it
Facility Name
Citta della Salute
City
Turin
ZIP/Postal Code
10128
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabrizio D'Ascenzo, MD
Phone
0116336023
Email
fabrizio.dascenzo@gmail.com
First Name & Middle Initial & Last Name & Degree
Fabrizio D'Ascenzo, MD

12. IPD Sharing Statement

Learn more about this trial

OCT Guided vs COmplete Pci in patieNts With sT Segment Elevation myocArdial infarCtion and mulTivessel Disease

We'll reach out to this number within 24 hrs